AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Efficacy and Safety of Dapagliflozin in Combination With Metformin in Type 2 Diabetes Patients
Phase 3
Completed
- Conditions
- Type 2 Diabetes
- Interventions
- First Posted Date
- 2008-04-17
- Last Posted Date
- 2015-03-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1217
- Registration Number
- NCT00660907
- Locations
- 🇬🇧
Research Site, Trowbridge, United Kingdom
Breast Cancer Tumor Care Observational Programme
- First Posted Date
- 2008-04-17
- Last Posted Date
- 2012-06-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 150
- Registration Number
- NCT00660244
- Locations
- 🇦🇹
Research Site, Graz, Austria
Non-Interventional Study of Cough Variant Asthma Treatment With Pulmicort®Respules® in Children Outpatients
Completed
- Conditions
- Cough Variant Asthma
- First Posted Date
- 2008-04-17
- Last Posted Date
- 2009-05-28
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 914
- Registration Number
- NCT00660114
- Locations
- 🇨🇳
Research Site, Wenzhou, Zhejiang, China
Study in Schizophrenic In-patients Treated With Quetiapine Prolong or Oral Risperidone at Flexible Dose
- First Posted Date
- 2008-04-17
- Last Posted Date
- 2010-09-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 29
- Registration Number
- NCT00660595
- Locations
- 🇫🇮
Research Site, Turku, Finland
Utilization Patterns of Pulmicort in Real Life Practice
Completed
- Conditions
- Asthma
- First Posted Date
- 2008-04-17
- Last Posted Date
- 2010-12-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 260
- Registration Number
- NCT00660569
- Locations
- 🇪🇸
Research Site, Toledo, Spain
Retrospective Brazilian Study of Fulvestrant in Advanced Breast Cancer
- First Posted Date
- 2008-04-17
- Last Posted Date
- 2010-01-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 200
- Registration Number
- NCT00660803
- Locations
- 🇧🇷
Research Site, Sao Paulo, SP, Brazil
Local Phase IV, Gastroesophageal Reflux Disease (GERD) Sleep Study US
Phase 4
Completed
- Conditions
- Gastroesophageal Reflux Disease
- Interventions
- Drug: PlaceboDrug: Esomeprazole
- First Posted Date
- 2008-04-17
- Last Posted Date
- 2015-03-02
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 276
- Registration Number
- NCT00660660
- Locations
- 🇺🇸
Research Site, Bellevue, Washington, United States
Assessment of the Efficacy of Rosuvastatin in Patient Groups With a Dissimilar Risk Profile in an Observational Study (HEROS)
Completed
- Conditions
- DiabetesCoronary Heart DiseasePeripheral Vascular DiseaseHypercholesterolemiaCerebrovascular Accident
- Interventions
- First Posted Date
- 2008-04-17
- Last Posted Date
- 2009-03-16
- Lead Sponsor
- AstraZeneca
- Registration Number
- NCT00660764
Evaluation of Patient Characteristics and Treatment Approaches to Patients With Bipolar Disorder in Turkey
Completed
- Conditions
- Bipolar Disorder
- First Posted Date
- 2008-04-17
- Last Posted Date
- 2009-05-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1018
- Registration Number
- NCT00660712
- Locations
- 🇹🇷
Research Site, Trabzon, Turkey
Study Using the Environmental Exposure Unit (EEU) to Assess the Onset of Action of Ciclesonide, Applied as a Nasal Spray in the Treatment of Seasonal Allergic Rhinitis (BY9010/M1-407)
Phase 3
Completed
- Conditions
- Rhinitis, Allergic, SeasonalHay Fever
- Interventions
- Drug: CiclesonideDrug: Placebo
- First Posted Date
- 2008-04-16
- Last Posted Date
- 2016-12-02
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 420
- Registration Number
- NCT00659503
- Locations
- 🇨🇦
Altana/Nycomed, Kingston, Ontario, Canada
© Copyright 2025. All Rights Reserved by MedPath